A B S T R A C T This study
INTRODUCTION
The nature and physiologic roles of the aldosteroneinduced protein have been a subject of disparate claims. Edelman and Fanestil (1) [1325] [1326] [1327] [1328] [1329] [1330] [1331] [1332] [1333] (FMN)1 from [14C]riboflavin in both the kidney and liver of the intact rat. They could not determine whether this observed effect was a result of ACTH per se or of an effect of the steroid hormones elaborated by the ACTH. Of considerable interest, therefore, is an antecedent report of Laszt and Verzar (3) in 1935 that asserts that the formation of FMN from riboflavin was promoted by the hormones ofthe adrenal cortex. The possibility that aldosterone increased the activity of the mitochondrial flavoprotein-linked NADH dehydrogenase (1) prompted Tan and Trachewsky (4) to investigate the influence of aldosterone on the formation of renal [14C]flavin coenzymes from [14C]riboflavin. We concluded from these latter studies (4) that mineralocorticoids specifically increased the formation of renal [14C]flavin adenine dinucleotide (FAD) because spironolactone effectively blocked this aldosterone-induced increase. The dose level of spironolactone employed in these studies had already been shown to inhibit the reabsorption of Na+ and secretion of K+ as a result of the administration of aldosterone to bilaterally adrenalectomized rats.2 This specific aldosterone antagonist had no effect by itself in the absence of aldosterone administration to the adrenalectomized rats.
This present investigation was undertaken to examine the possible cause-effect relationship between (5) reported that there was a decrease in the biogenesis of flavoprotein components in hepatic mitochondria from riboflavin-deficient rats which could be reversed by an i.p. injection of riboflavin in 7,8-dimethyl-10-(2'-hydroxyethyl) isoalloxazine (U-2113) and 7,8-dimethyl-10-formylmethyl isoalloxazine (U-1003) were gifts from the Upjohn Co., Kalamazoo, Mich. Experimental conditions. All experiments were performed with male Sprague-Dawley rats that weighed between 185 and 210 g. These animals were bilaterally adrenalectomized, fed, ad libitum on Purina rat chow (Ralston Purina Company Inc., St. Louis, Mo.), and given drinking water which contained 5% dextrose and 1% NaCl for 3 days. The night before the experiment on the 4th day, each rat received an i.p. injection of dexamethasone (15 ,ug/100 g body wt) and the food and water were removed. We have found that this dose of dexamethasone will suppress ACTH in our rats.3 Dexamethasone was administered for the reasons already documented (4) . On the morning of the 4th day, the animals were all weight-matched and divided into four equal and separate groups. At zero time, all rats were injected i.p. with a single dose of 5.0 ,LCi [2-14C] riboflavin/200 g body wt, and various other solutions of aldosterone and(or) riboflavin analogue. The first group served as control, and received only the vehicles for all other injections. The second group was administered aldosterone (1.5 i±g/100 g body wt). The third group received injections of aldosterone (1.5 gg/100 g body wt) and varying doses of one or the other of the two riboflavin analogues 7,8-dimethyl-10-(2'hydroxyethyl) isoalloxazine and 7,8-dimethyl-l1-formylmethyl isoalloxazine. The fourth group was treated only with the same varying doses of one or the other of the two riboflavin analogues as the third group.
30 min after i.p. injections, the urethral outflow tracts of the rats were ligated under light ether-anesthesia and each animal was injected i.p. with 4 ml of 0.9% saline. 3 h later, the rats were sacrificed by decapitation, urine was aspirated from the bladder via an abdominal incision, and the kidneys were removed and quick-frozen for analysis of their radioactive flavin content the following day. The greater in the aldosterone-treated than in control animals, but this difference was not statistically significant (P > 0.05).
In the same animals, as well as additional control and mineralocorticoid-treated ones, aldosterone administration significantly decreased the urinary output of Na+ by 50% (P < 0.0005) and increased that of K+ by 55% (P < 0.0005) 3.5 h after hormone treatment (Table II [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] ,ug/1OOg body wt of 7,8-dimethyl-10-formylmethyl isoalloxazine simultaneously with aldosterone resulted in a significant 26±9 to 124±58% (P < 0.05) increase in the urinary excretion of Na+ when compared to that as a result of aldosterone administration alone (Fig. 1) . The optimal effect of the riboflavin analogue was found at 20 ugI/100 g body wt where the increase in urinary output of Na+ was 124 ±58% (P < 0.05) when compared to that as a result of aldosterone administration alone. At the lower-dose levels of 8.5 and 10 ,ugl 100 g body wt and the higher ones of 30 (Fig. 2) . At the lower-dose levels of 10 ,ugI100 g body wt and the higher levels of 30 Essentially the same results were obtained when the riboflavin analogue 7,8-dimethyl-10-(2'-hydroxyethyl) isoalloxazine was investigated. The administration of 10-21 ,ug/100 g body wt of this analogue in tandem with aldosterone evoked a significant increase of 64 ±24 to 92±32% (P < 0.025) in the urinary excretion of Na+ when compared with that as a result of aldosterone administration alone (Fig. 3) . At the lower-dose levels of 4.5 and 7 ,ug/100 g body wt and the higher levels of 25 and 30 ,ug/100 g body wt, this particular riboflavin analogue did not significantly alter the urinary excretion of Na+ as a result of aldosterone treatment. At all dose levels investigated, this analogue, too, had no significant effect on the increased excretion of K+ by aldosterone.
The same dose levels of 7,8-dimethyl-10-(2'-hydroxyethyl) isoalloxazine that significantly increased the urinary excretion of Na+ when administered in tandem with aldosterone (10-21 gg/100 g body wt) also significantly diminished the incorporation of [ It is worth noting that in no group of animals in the present investigation was there a significant effect of aldosterone administration upon the radioactive riboflavin concentration in the kidney. The data found are compatible with the view that vitamin transport into kidney may not be a critical locus of hormonal control, and that regulation of enzyme activities may be the main control point.
If the observed hormonal effect was secondary to an increase of the intracellular-riboflavin pool, then when the animals were administered aldosterone in tandem with one or the other of the two riboflavin analogues, we should have definitely observed an increase in the amount of renal [14C]riboflavin because our data show that under these conditions the analogues diminish the conversion of riboflavin to FMN when used at the appropriate dose levels. The radioactivity as renal ['4C]riboflavin, however, was essentially similar for the control group of rats and those administered aldosterone in tandem with one or the other of the analogues. The dose levels at which we have used our two riboflavin analogues should not present any problem ofacute or chronic toxicity. In studies at the Upjohn Company the estimated mean lethal dose of 7,8-dimethyl-10-(2'-hydroxyethyl) isoalloxazine, when administered i.p. to mice, was in excess of 1,000 mg/kg body wt.4 In rats, doses of20 mg/kg body wt gave a response in decreased weight gain but no other gross evidence of riboflavin deficiency was noted. Observations with 7,8-dimethyl-10-formylmethyl isoalloxazine were essentially equivalent to those with the hydroxyethyl derivative. 5 An interesting point worth mentioning is that although the analogues were supplied as chemically prepared derivatives of riboflavin, both occur as natural catabolites of the vitamin, and are excreted into urine and milk. Presumably, they arise as a result of bacterial degradation, especially in rumen where microfloral activity is high (26, 27) .
In adrenalectomized animals, increased excretion of Na+ and a decreased K+ excretion in urine are commonly observed. Aldosterone replacement increases urinary loss of K+, whereas Na+ excretion is reduced (Table II) , so that the urinary Na+-K+ ratio returns to a normal level. Therefore, the concept of an aldosteronedependent Na+-K+ exchange in the distal tubule has been widely accepted. However, the physiological response to aldosterone in the adrenalectomized animal can be divided into two separable responses; namely, the antinatriuretic and the kaliuretic response, and this has been reported for the rat (1, 28) and the dog (29, 30) . We found that the two riboflavin analogues at all dose levels investigated exerted no significant effect on the increased urinary excretion of K+ by aldosterone, whereas they did (at certain dose levels) counteract the effect of aldosterone on the decreased urinary output of Na+. These observations are certainly compatible with the view that the antinatriuretic and kaliuretic responses to aldosterone can be separated.
The results of this present investigation strongly suggest that the enhanced biosynthesis of renal FMN and FAD may be a causative factor in the increased reabsorption of Na+ after aldosterone replacement; and, consequently, riboflavin analogues may function as a novel class of anti-mineralocorticoids.
